| 英文名稱 | Navitoclax (ABT-263) |
|---|---|
| 中文名稱 | Navitoclax (ABT-263) |
| CAS號(hào) | 923564-51-6 |
| 分子式 | C47H55ClF3N5O6S3 |
| 分子量 | 974.61 |
| 外觀 | White to light yellow powder |
| 儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
| 英文名稱 | Navitoclax (ABT-263) |
|---|---|
| 中文名稱 | Navitoclax (ABT-263) |
| CAS號(hào) | 923564-51-6 |
| 分子式 | C47H55ClF3N5O6S3 |
| 分子量 | 974.61 |
| 外觀 | White to light yellow powder |
| 儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Navitoclax, also known as ABT-263, is an orally bioavailable, synthetic small-molecule antagonist of a subset of the B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w and prevents their binding to the apoptotic effectors Bax and Bak proteins, which may trigger apoptosis in tumor cells overexpressing Bcl-2, Bcl-XL, and Bcl-w.